Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
Appointed COO
KERYX BIOPHARMACEUTICALS INC (KERX) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/13/2018 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Agreement and Plan of Merger, by and among Akebia Therapeutics, Inc., Alpha Therapeutics Merger Sub Inc. and Keryx Biopharmaceuticals, Inc. (incorporated by reference to Exhibit 2.1 to Keryx's Current Report on Form 8-K filed on June 28, 2018)",
"Amended and Restated Certificate of Incorporation of Keryx Biopharmaceuticals, Inc",
"Amended and Restated Bylaws of Keryx Biopharmaceuticals, Inc"
11/08/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results"
10/25/2018 8-K Entry into a Material Definitive Agreement, Other Events
10/01/2018 8-K Quarterly results
08/08/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : August 8, 2018 Keryx Biopharmaceuticals, Inc. Delaware 000-30929 13-4087132 One Marina Park Drive, 12 th Floor Boston, Massachusetts 02210 466-3500 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act. ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act. ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act. ☐ Pre-commencement communications pursuant to Rule...",
"Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results",
"Investor presentation to be presented by Keryx Biopharmaceuticals, Inc. on August 8, 2018"
07/20/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "EXHIBIT A - COLLATERAL DESCRIPTION"
07/03/2018 8-K Submission of Matters to a Vote of Security Holders
Docs: "FORM 8-K"
06/28/2018 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among Akebia Therapeutics, Inc., Alpha Therapeutics Merger Sub Inc. and Keryx Biopharmaceuticals, Inc.",
"Amendment to Amended and Restated Bylaws",
"Notes Conversion Agreement, by and among Keryx Biopharmaceuticals, Inc., Baupost Group Securities, L.L.C. and, with respect to certain sections only, Akebia Therapeutics, Inc",
"Voting Agreement, by and between Keryx Biopharmaceuticals, Inc. and Muneer Satter",
"Voting Agreement, by and between Akebia Therapeutics, Inc. and Baupost Group Securities, L.L.C",
"Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease"
06/15/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement between Keryx Biopharmaceuticals, Inc. and Mr. Madison",
"Separation Agreement between Keryx Biopharmaceuticals, Inc. and Mr. Madison"
05/25/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : May 25, 2018 Keryx Biopharmaceuticals, Inc. Delaware 000-30929 13-4087132 One Marina Park Drive, 12 th Floor Boston, Massachusetts 02210 466-3500 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act. ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act. ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act. ☐ Pre-commencement communications pursuant to Rule 1...",
"Keryx Biopharmaceuticals Announces Data from an Investigator Sponsored Trial of Ferric Citrate in Patients with Advanced Chronic Kidney Disease in a Late-Breaking Presentation at the 55 th Annual ERA/EDTA Today in Copenhagen Conference Call Today at 8:30 a.m. EST"
05/10/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Notes Exchange Agreement, between Keryx Biopharmaceuticals, Inc. and Baupost Group Securities, L.L.C",
"Indenture, between Keryx Biopharmaceuticals, Inc. and The Bank of New York Mellon Trust Company, N.A",
"Registration Rights Agreement, between Keryx Biopharmaceuticals, Inc. and Baupost Group Securities, L.L.C",
"Keryx Biopharmaceuticals Announces First Quarter 2018 Financial Results",
"Investor presentation to be presented by Keryx Biopharmaceuticals, Inc. on May 10, 2018"
04/30/2018 8-K Quarterly results
02/16/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K"
02/07/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results",
"Investor presentation to be presented by Keryx Biopharmaceuticals, Inc. on February 7, 2018"
12/27/2017 8-K Termination of a Material Definitive Agreement
Docs: "FORM 8-K"
12/21/2017 8-K Entry into a Material Definitive Agreement
Docs: "FORM 8-K"
12/19/2017 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amended and Restated Bylaws of Keryx Biopharmaceuticals, Inc. adopted on December 13, 2017",
"Amended and Restated Bylaws of Keryx Biopharmaceuticals, Inc. adopted on December 13, 2017"
12/13/2017 8-K Entry into a Material Definitive Agreement
Docs: "FORM 8-K"
11/07/2017 8-K Quarterly results
Docs: "FORM 8-K",
"Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results",
"Investor presentation to be presented by Keryx Biopharmaceuticals, Inc. on November 7, 2017",
"U.S. FDA Approves Auryxia ® Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis"
09/13/2017 8-K Quarterly results
09/01/2017 8-K Entry into a Material Definitive Agreement
07/27/2017 8-K Form 8-K - Current report:
07/27/2017 8-K Quarterly results
Docs: "Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance",
"Investor presentation to be presented by Keryx Biopharmaceuticals, Inc. on July 27, 2017"
06/13/2017 8-K Form 8-K - Current report
05/04/2017 8-K Form 8-K - Current report
04/10/2017 8-K Form 8-K - Current report
03/01/2017 8-K Form 8-K - Current report
01/09/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
10/17/2016 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure
08/01/2016 8-K Quarterly results
Docs: "Keryx Biopharmaceuticals Announces Interruption in Supply of Auryxia ® and Second Quarter 2016 Financial Results"
06/21/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/27/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Keryx Biopharmaceuticals, Inc. Amended and Restated 2013 Incentive Plan",
"Keryx Biopharmaceuticals, Inc. Fourth Amended and Restated Directors Equity Compensation Plan"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy